

James Francis Chmiel, M.D., M.P.H.

office: 216-844-3267

fax: 216-844-5916

email: james.chmiel@uhhs.com

Education

1986	B.S.	Microbiology	University of Notre Dame, Notre Dame, IN
1991	M.D.		University of Michigan Medical School, Ann Arbor, MI
1991	M.P.H.	Epidemiology	University of Michigan School of Public Health, Ann Arbor, MI
1991-1992	Internship	Pediatrics	Children's Memorial Hospital/Northwestern University Medical School, Chicago, IL
1992-1994	Residency	Pediatrics	Children's Memorial Hospital/Northwestern University Medical School, Chicago, IL
1995-1999	Fellowship	Pediatric Pulmonology	University Hospitals of Cleveland/Case Western Reserve University School of Medicine, Cleveland, OH

Brief Chronology of Employment and Appointments

Current

2001-present	Assistant Professor of Pediatrics, Division of Pediatric Pulmonology, Case Western Reserve University School of Medicine at Rainbow Babies and Children's Hospital, Cleveland, OH
2004-present	Associate Director, LeRoy W. Matthews Cystic Fibrosis Center, Division of Pediatric Pulmonology, Case Western Reserve University School of Medicine at Rainbow Babies and Children's Hospital, Cleveland, OH
2004-present	Director of Education, Division of Pediatric Pulmonology, Case Western Reserve University School of Medicine at Rainbow Babies and Children's Hospital, Cleveland, OH
2001-present Pulmonology,	Fellowship Training Director, Division of Pediatric Case Western Reserve University School of Medicine at Rainbow Babies and Children's Hospital, Cleveland, OH
1998-present	Attending Staff, University Hospitals of Cleveland, Cleveland, OH

Past

2000-2003	Co-Director of the Infant Pulmonary Function Laboratory, Rainbow Babies and Children's Hospital, Cleveland, OH
1999-2001	Instructor of Pediatrics, Division of Pediatric Pulmonology, Case Western Reserve University School of Medicine, Cleveland, OH
1998-1999	Clinical Instructor, Division of Pediatric Pulmonology, University Hospitals of Cleveland, Cleveland, OH
1998-1999	Fourth Year Research Fellow, Division of Pediatric Pulmonology, University Hospitals of Cleveland, Cleveland, OH
1995-1998	Fellow Staff, University Hospitals of Cleveland
1994-1995	Instructor of Pediatrics, General and Academic Pediatrics, Northwestern University Medical School, Chicago, IL
1994-1995	Attending Physician, Children's Memorial Hospital, Chicago, IL
1994-1995	Clinical Instructor, Pediatric Allergy and Immunology, Children's Memorial Hospital, Chicago, IL
1991-1994	Resident HouseStaff, Children's Memorial Hospital/Northwestern University Medical School, Chicago, IL
1987	Summer Research Assistant, Upjohn Company, Kalamazoo, MI
1986	Summer Research Assistant, Upjohn Company, Kalamazoo, MI
1985-1986	Student Research Assistant, University of Notre Dame, Notre Dame, IN

Honors and Awards

1985	Alpha Epsilon Delta Premedical Honor society
1986	Phi Beta Kappa Honor Society
1986	B.S. granted with High Honors, University of Notre Dame
1992	PL-1 Teacher of the Year, Children's Memorial Hospital
1997-1998	Cystic Fibrosis Foundation Third Year Clinical Fellowship
1997	Glaxo Wellcome Pulmonary Fellowship Award (<i>Declined due to acceptance of CFF Third Year Clinical Fellowship</i>)
1997	Distinguished Residents and Fellows Asthma Education Scholarship Program
1998	Post Doctoral Fellows Outstanding Research Award, Rainbow Babies and Children's Hospital Science Day
1998-1999	Cystic Fibrosis Foundation Fourth Year Clinical Fellowship
1999-2002	Harry Shwachman Clinical Investigator Award, Cystic Fibrosis Foundation
2001	Pediatric Pearl's Day Award, Rainbow Babies and Children's Hospital
2002	Honorable Mention for Teaching Excellence, Rainbow Babies and Children's Hospital
2003	Honorable Mention for Teaching Excellence, Rainbow Babies and Children's Hospital
2004	Pediatric Pearl's Day Award, Rainbow Babies and Children's Hospital
2004	Honorable Mention for Teaching Excellence, Rainbow Babies and Children's Hospital

Grants

Active Grants

Cystic Fibrosis Foundation: *Effect of CFTR inhibition on Lymphocyte Cytokines*, 4/1/04-3/31/06; P.I. J.F. Chmiel, M.D., M.P.H.

Cystic Fibrosis Foundation: *Effect of Simvastatin on CF Airway Inflammation*, 4/1/04-3/31/07; Site P.I. J.F. Chmiel, M.D., M.P.H.

RFP National Institutes of Health/NIAID (contract): *NIAID Inner City Asthma Consortium: Immunologic approaches to reduce asthma*, 9/30/02-9/29/08; Site P.I. C. M. Kerckmar, M.D., Site Co-PI J.F. Chmiel, M.D., M.P.H.

Cystic Fibrosis Foundation: *Therapeutics Development Center*, 4/1/03-10/31/07; P.I. M.W. Konstan, M.D., Co-PI J.F. Chmiel, M.D., M.P.H.

Cystic Fibrosis Foundation: *Evaluation of Pulmonary Function Tests from Raised Lung Volumes as Outcome Measures for Clinical Trials in Infants with Cystic Fibrosis*, 2/1/03-1/31/06; Site P.I. (2/1/03-12/31/03): J.F. Chmiel, M.D., M.P.H.; Site Co-PI (1/1/04-1/31/06): J.F. Chmiel, M.D., M.P.H.

Past Grants

Corus Pharma, Inc. (contract): *A Blinded, Multicenter, Randomized, Placebo-Controlled Trial with Aztreonam for Inhalation (AI) in Cystic Fibrosis Patients with Lung Disease Due to P. aeruginosa Infection*, 12/1/03-6/30/04; P.I. J.F. Chmiel, M.D., M.P.H.

National Institutes of Health P30 DK27651: *Core Center: Cystic Fibrosis*, 4/1/01-3/31/06; Center Director – P. B. Davis, M.D., Ph.D., *Feasibility Project: Role of IL-6 in CF Airway Inflammation* 4/1/02-3/31/04; Feasibility Project Director: J.F. Chmiel, M.D., M.P.H.

Cystic Fibrosis Foundation: *Effect of Mutant CFTR Expression on Lung Inflammation*, 7/1/00-6/30/03; P.I. J. F. Chmiel, M.D., M.P.H.

Cystic Fibrosis Foundation: *Consequences of IL-10 Deficiency in CF Lung Disease*, 11/15/01-11/14/03; P.I. M. Berger, M.D., Ph.D.; Co-PI J.F. Chmiel, M.D., M.P.H.

Scios Inc. (contract): *Evaluation of safety and Efficacy of Scios p38 MAP Kinase Inhibitor(s) in Preclinical Models of Cystic Fibrosis Lung Disease*, 12/01/01-6/30/03; P.I. M Berger, M.D., Ph.D., Co-PI J.F. Chmiel, M.D., M.P.H.

Cystic Fibrosis Foundation: *Therapeutics Development Center*, 4/1/98-3/31/03; P.I. M.W. Konstan, M.D., Co-PI J.F. Chmiel, M.D., M.P.H.

Chiron Corporation (Contract): *A Phase I Trial Comparing Safety, Serum Pharmacokinetics and Delivery Time of a Concentrated Tobramycin Solution for Inhalation (120mg/ml) Delivered by an Invacare Mobile™ Compressor to TOBI (60mg/ml) Delivered by Devilbiss Pulmoaide™ Compressor in Young (\$6 months to <12 years old) Cystic Fibrosis Patients.* 8/15/02-12/30/02; P.I. M.W. Konstan, M.D., Co-PI J.F. Chmiel, M.D., M.P.H.

Cystic Fibrosis Foundation, Harry Shwachman Clinical Investigator Award: *The Role of IL-10 in CF Airway Inflammation*, 7/1/99-6/30/02; P.I. J.F. Chmiel, M.D., M.P.H.

Cystic Fibrosis Foundation, Third and Fourth Year Clinical Fellowship Award: *Interleukin-10 in Cystic Fibrosis Lung Disease*, 7/1/97-6/30/99; P.I. J.F. Chmiel, M.D., M.P.H.

Boehringer-Ingelheim (Contract): *A Randomized, Double-Blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses (15-Day Dosing) of BIIL284BS in Adult (150 mg) and Pediatric (75 mg) Cystic Fibrosis Patients.* 6/1/02-11/1/02; P.I. M.W. Konstan, M.D. Co-PI J.F. Chmiel, M.D., M.P.H.

Boehringer-Ingelheim (Contract): *A Randomised, Double-Blind Within Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis Patients.* 10/1/01-7/31/02; P.I. M.W. Konstan, M.D. Co-PI J.F. Chmiel, M.D., M.P.H..

Cystic Fibrosis Foundation/Inspire: *A Phase 1b/2a Ascending Dose Cohort Study to Assess the Safety, Tolerability, and Effects of Five Dose Levels of INS 37217 and Placebo Followed by Five Days Twice Daily Treatment with Maximum Tolerated Dose Administered by Inhalation via the Pari LC Star Nebulizer in Adult and Pediatric Patients with Cystic Fibrosis*, 4/09/01-06/30/02, P.I. L. J.H. Milgram; Co-PI J.F. Chmiel

Cystic Fibrosis Foundation/NIH: *A Phase II Randomized Trial of Tobramycin for Inhalation in Young Children with Cystic Fibrosis (TOBI Efficacy Study)*, 2/1/00-4/30/02; P.I. M.W. Konstan, M.D.; Co-PI J.F. Chmiel, M.D., M.P.H.

Cystic Fibrosis Foundation/Therapeutics Development Network: *Validation of Sputum Induction as an Outcome Measure for Lower Airway Sampling in Patients with Cystic Fibrosis*, 4/01/01-3/31/02; P.I. J.F. Chmiel

Cystic Fibrosis Foundation/Pathogenesis Corporation: *Tobi Nebulizer Comparison Trial: 6/2000-12/2000*; P.I. L.J. Milgram, M.D.; Co-PI J.F. Chmiel, M.D., M.P.H.)

Publications

Articles

Chmiel JF and Konstan MW. Anti-Inflammatory medications in cystic fibrosis: Selecting the most appropriate agent. *Am. J. Respir. Med.* 2003 (In Press)

Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, and Aitken ML. Inflammatory and

microbiologic markers in induced sputum following IV antibiotics in cystic fibrosis. *Am. J. Respir. Crit. Care Med.* 2003;168:1471-1475.

Chmiel JF and Davis PB. State of the Art: Why do the lungs of CF patients get infected and why can't they clear infection? *Respir. Res.* 2003;4:8-21 (<http://respiratory-research.com/content/4/1/8>)

Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Kirchner HL, and Berger M. Prolonged inflammatory response to acute pseudomonas challenge in IL-10 knockout mice. *Am. J. Respir. Crit. Care Med.* 2002;165:1176-1181.

Soltys J, Bonfield T, Chmiel J, and Berger M. Functional IL-10 deficiency in the lung of cystic fibrosis (*cfr* -/-) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar Macrophages. *J. Immunol.* 2002;168:1903-1910.

Chmiel JF, Berger M, and Konstan MW. The role of inflammation in the pathophysiology of cystic fibrosis lung disease. *Clin. Rev. Allergy Immunol.* 2002;23:5-28.

Chmiel JF, Konstan MW, Knesebeck JE, Hilliard JB, Bonfield TL, Dawson DV, and Berger M. IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. *Am. J. Respir. Crit. Care Med.* 1999;160:2040-2047.

Lane, JR, Chmiel, JF, and Zahka, KG. Marfan syndrome and asthma: A review. *Pediatr. Asthma All. Immunol.* 1999;13:183-188.

Chmiel JF, Drumm ML, Konstan MW, Ferkol TW, Kercksmar CM. Pitfall in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis. *Pediatrics* 1999;103:823-826.

Chmiel JF, Wessel HU, Targoff IN, and Pachmann LM. Pulmonary fibrosis in a child with anti-Jo-1 antibody. *J. Rheum.* 1995;22:762-765.

Editorial Correspondence

Chmiel J: Paper Report on "Oxidant lung injury in cystic fibrosis". *Respir. Res.* www.respiratory-research.com 2001;2:68563.

Chmiel JF: Paper Report on "Genetic screening in cystic fibrosis". *Respir. Res.* www.respiratory-research.com 2001;2:68530.

Abstracts

Chmiel JF, Konstan MW, Longville T, and Berger M. *In vitro* stimulation of $\Delta F508$ heterozygous primary airway epithelial cells with *P. aeruginosa* does not result in increased inflammatory mediator production. *Pediatr. Pulmonol.* 2003;S25:270-271.

Chmiel JF. Intracellular signaling cascades as targets for anti-inflammatory therapy. *Pediatr. Pulmonol.* 2002;S24:143-144.

Ordonez CL, Gibson RL, Julia E, McNamara S, Accurso FJ, Burns JL, Zeitlin PL, Daines C, Retsch-Bogart GZ, Chmiel JF, Henig NR, Aitken ML. Validation of sputum induction as an outcome measure for lower airway sampling in patients with cystic fibrosis (CF). *Pediatr. Pulmonol.* 2002;S24:299.

Saadane A, Chmiel J, Soltys J, and Berger M. IL-10 knockout (-/-) mice as models for the immunoregulatory disorders of CF. *Pediatr. Pulmonol.* 2001;S22:274.

Chmiel JF, Konstan MW, Krenicky JE, Saadane A, and Berger M. IL-10 deficiency is associated with excessive and prolonged inflammation after endobronchial *P. aeruginosa* infection and mimics cystic fibrosis. *Pediatr. Res.* 2001;49:458A.

Soltys J, Bonfield T, Chmiel J, and Berger M. Increased B7 expression and APC activity of alveolar macrophages from IL-10 and CFTR knockout mice. *FASEB J.* 2001;15 (part 1).

Chmiel JF, Konstan MW, Krenicky JE, Saadane A, and Berger M: Persistent lung inflammation after clearance of *Pseudomonas aeruginosa* in IL-10 knockout mice. A potential mechanism for "inflammation in the apparent absence of infection" in CF infants. *Pediatr. Pulmonol.* 2000;S20:301.

Berger M, Bonfield T, Chmiel J, and Konstan M. Cytokines in cystic fibrosis lung disease: Role of the epithelial cell. *Clin. Microbiol. and Infect.* 1999.

Chmiel JF, Knesebeck JE, Hilliard JB, Bonfield TL, Konstan MW, and Berger M. IL-10 regulates inflammation in chronic endobronchial *Pseudomonas aeruginosa* infection in mice. *Pediatr. Pulmonol.* 1998;S17:608.

Chmiel JF, Knesebeck JE, Hilliard JB, Bonfield TL, Konstan MW, and Berger M. Significance of IL-10 Deficiency in CF Lung Disease and Potential Use of IL-10 in Therapy. 22nd European CF Conference, Berlin, 1998.

Chmiel JF, Knesebeck JE, Hilliard JB, Konstan MW, and Berger M. IL-10 ameliorates excessive inflammation in chronic *Pseudomonas aeruginosa* infection in mice. *Pediatr. Res.* 1998;43:331A.

Chmiel JF, Wessel HU, Targoff IN, and Pachmann LM. Pulmonary fibrosis in a child with anti-Jo-1 antibody. American College of Rheumatology Regional Meetings, Chicago, 1994.

Book Chapters and Monographs

Chmiel JF and Davis PB. Inflammatory Responses in the Cystic Fibrosis Lung. In: KL Kirk and DC Dawson (eds.), *The CFTR Chloride Channel*. Georgetown, TX: Landes Bioscience, 2003;10:160-180.

Chmiel JF, Konstan MW, and Berger M. Murine Models of CF Infection and Inflammation. In: WR Skach (ed.), *Methods in Molecular Medicine: Cystic Fibrosis Methods and Protocols*. Totowa, NJ: The Humana Press Inc., 2002;70:495-515.